Epizyme (NASDAQ:EPZM) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Tuesday.

A number of other research analysts have also weighed in on EPZM. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a report on Monday, August 7th. Leerink Swann reaffirmed an “outperform” rating and set a $28.00 target price (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $20.00 target price on shares of Epizyme in a report on Friday, September 15th. Cann reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday, September 19th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $22.67.

Epizyme (EPZM) opened at $12.70 on Tuesday. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. research analysts forecast that Epizyme will post -2.23 EPS for the current year.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the completion of the transaction, the insider now owns 23,123 shares of the company’s stock, valued at $388,697.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David M. Mott acquired 200,000 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were acquired at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. 25.20% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in Epizyme by 8.9% in the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Epizyme by 3.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 1,068 shares during the last quarter. Rhumbline Advisers lifted its position in Epizyme by 2.6% in the 2nd quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 1,257 shares during the last quarter. Principal Financial Group Inc. lifted its position in Epizyme by 1.5% in the 2nd quarter. Principal Financial Group Inc. now owns 95,572 shares of the biopharmaceutical company’s stock worth $1,443,000 after buying an additional 1,399 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in Epizyme by 3.1% in the 1st quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 2,093 shares during the last quarter. Institutional investors own 85.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/12/07/epizyme-epzm-stock-rating-upgraded-by-bidaskclub.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.